Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial).
Eur J CancerSep 10, 2026 (epub)
Clinical ResearchOncology (Medical)
Yoshiaki Nagatani, Naoko Chayahara, Hironaga Satake et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter phase II study evaluated the efficacy and safety of triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 in 30 patients with advanced pancreatic cancer. The study found an objective response rate of 63.3% and a disease control rate of 86.7%, indicating significant antitumor activity and potential for surgical conversion in this population.
Key findings
- Objective response rate was 63.3% (95% CI, 45.5-78.2).
- Disease control rate reached 86.7%, with only 6.7% experiencing progressive disease.
- Median progression-free survival was 9.0 months (95% CI, 7.5-10.5).
- In locally advanced disease, the objective response rate was 100%, with 60% undergoing conversion surgery.
Why it matters
The findings suggest that the combination of S-1 with Gemcitabine and Nab-paclitaxel may enhance treatment outcomes in advanced pancreatic cancer, particularly in patients with locally advanced or borderline resectable disease, which could influence future therapeutic strategies.